FDA accepts resubmitted BLA for Xbrane’s Lucamzi
Bottom line
Xbrane said the US Food and Drug Administration has accepted the resubmitted biologics license application for Lucamzi, its proposed biosimilar to Lucentis (ranibizumab), and assigned a BsUFA target action date of October 29, 2026. The candidate is being developed with STADA and is slated for US commercialization by Valorum Biologics under the Lucamzi brand. The filing follows an April 2026 resubmission that, according to Xbrane, addressed issues raised in an October 2025 complete response letter tied to manufacturing-site observations rather than new clinical or biosimilarity questions. Xbrane’s ranibizumab biosimilar is already approved and marketed in Europe as Ximluci, where it launched in 2023. (mfn.se)
Why it matters: For veterinary professionals, this is mostly a signal about the broader biosimilars and FDA manufacturing-review environment, not a direct change to companion animal therapeutics. Still, the case is worth watching because it shows how manufacturing compliance, not just clinical comparability, can determine timelines for biologics. It also underscores the commercial pressure in the ranibizumab biosimilar market: analyst commentary has noted slower-than-expected uptake in Europe and rising price competition, factors that could shape launch strategy if Lucamzi reaches the US market. (mfn.se)
What to watch: The next milestone is the FDA’s decision by October 29, 2026, and any updates on launch readiness, reimbursement, or market access in the US. (mfn.se)
Key facts
- Product
- Lucamzi
- Reference product
- Lucentis (ranibizumab)
- Regulatory status
- FDA accepted the resubmitted BLA
- FDA action date
- October 29, 2026
- Development partner
- STADA
- US commercialization partner
- Valorum Biologics
- Prior FDA issue
- October 2025 complete response letter
- Stated issue type
- Manufacturing-site observations
- Existing market
- Approved and marketed in Europe as Ximluci since 2023
Xbrane has cleared an important regulatory checkpoint in the US: the FDA has accepted the company’s resubmitted BLA for Lucamzi, its proposed biosimilar to Lucentis (ranibizumab), and set a BsUFA action date of October 29, 2026. The product is intended for US launch under the Lucamzi name, with STADA as Xbrane’s development partner and Valorum Biologics lined up to handle commercialization in the US. (mfn.se)
The acceptance matters because it follows a drawn-out regulatory path. Xbrane disclosed in March 2026 that it planned to resubmit in April or May after receiving further FDA feedback tied to a complete response letter issued in October 2025. According to the company, the remaining issues centered on observations at one manufacturing site, and the delay was described as a modest one. Xbrane has also said the FDA did not ask for additional clinical trials or further studies to demonstrate biosimilarity, suggesting the regulatory hurdle was operational rather than scientific. (mfn.se)
There’s also a longer history here. Xbrane’s ranibizumab biosimilar is already approved by the EMA and the UK’s MHRA, and has been marketed in Europe as Ximluci since 2023. That existing commercial footprint gives the company and its partners some real-world experience as they prepare for a possible US launch, even though the US market dynamics are different and likely tougher on price. (mfn.se)
On the commercial side, Xbrane and STADA previously licensed US rights to Valorum Biologics. Xbrane has said the agreement includes up to $45 million in license payments tied to upfront, regulatory, and sales milestones, plus royalties on net sales, split equally between Xbrane and STADA. Valorum is expected to lead sales, marketing, and other commercialization efforts in the US if approval comes through. (xbrane.com)
Industry perspective is more mixed than the filing acceptance alone might suggest. A recent Redeye research note described the ranibizumab biosimilar market as challenging, citing slower-than-expected uptake and increasing price pressure. The same note said some competitors have faced enough pricing pressure to pause commercialization efforts, underscoring that regulatory progress doesn’t automatically translate into a smooth launch or attractive margins. That’s analyst commentary, not company guidance, but it adds useful context around the commercial backdrop Lucamzi would enter. (res.cloudinary.com)
Why it matters: For veterinary professionals, this isn’t a practice-changing drug story, since Lucamzi is a human ophthalmology biosimilar. But it is a useful case study in how biologics move through the FDA system. The takeaway is that manufacturing readiness and inspection outcomes can be as decisive as the clinical package, especially for biosimilars. For animal health stakeholders watching biologics, compounding policy, or future biosimilar development in veterinary medicine, that’s a relevant signal about how tightly quality systems and supply chain execution are tied to approval timing. (mfn.se)
It also highlights a broader economic reality. Biosimilars are often framed as cost-saving alternatives, but market access depends on more than approval. Contracting, reimbursement, channel strategy, and competitive discounting all shape whether a biosimilar meaningfully expands access. Inference: if Lucamzi is approved on the new timeline, the bigger question may be not whether it can launch, but whether it can gain traction in a crowded ranibizumab market. That inference is supported by Xbrane’s existing European launch history and the analyst view that market uptake has been uneven. (mfn.se)
What to watch: Between now and October 29, 2026, the key issues are whether the FDA review stays on schedule, whether Xbrane or its partners disclose any remaining manufacturing or inspection updates, and how Valorum positions Lucamzi for reimbursement and distribution if approval is granted. (mfn.se)